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Objective. To investigate the characteristics of power Doppler (PD) subclinical synovitis in patients with 
rheumatoid arthritis (RA) who achieve clinical remission free from physical synovitis. 
Methods. Twenty-nine RA patients were consecutively enrolled.  All of the patients had achieved clinical 
remission [simplified disease activity index (SDAI)≦3.3] for at least 6 months at the musculoskeletal 
ultrasonography (MSKUS) examination.  Additionally, none of the patients exhibited tender joints at 68 sites 
or swollen joints at 66 sites.  MSKUS of bilateral wrist and finger joints, including the 1st – 5th MCP joints, 
1st IP joint and 2nd -5th PIP joints, was performed, and the findings obtained by gray scale (GS) and PD were 
graded on a semi- quantitative scale from 0 to 3. 
Results. Median disease duration upon the introduction of disease-modifying antirheumatic drugs (DMARDs) 
was 3 months, and that at MSKUS examination was 21 months.  The percentages of patients with PD synovitis 
in at least one joint were PD grade≧1; 58.6 %, PD grade≧2; 31.0 %, PD grade 3; 6.9 %.  The use of 
biological agents was low in patients with a PD synovitis grade≧2 (p < 0.05). The presence of US bone erosion 
was high by patient (p < 0.05) and by joint (p < 0.0001) with PD synovitis as compared to those without PD 
synovitis.  However, no correlations were found between PD synovitis measures and serum biomarkers 
including angiogenesis factors. 
Conclusion. PD subclinical synovitis correlates with several clinical characteristics, whereas conventional 
serum biomarkers are not useful to indicate the presence of subclinical PD synovitis. 
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Introduction  
Recently, the outcome for patients with rheumatoid arthritis (RA) has improved due to improvements in therapy, 
and “clinical remission” is a realistic therapeutic goal [1].  There are several definitions of “clinical remission” 
based on various composite scores, such as the Disease Activity Score (DAS), 28-joint count DAS (DAS28), 
Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and a Boolean definition 
as recently proposed by America College of Rheumatology (ACR) or European League Against Rheumatism 
(EULAR) [2].  The latter three criteria based on SDAI, CDAI and the Boolean definition are more stringent 
than those based on DAS28 [2].  The RA patients achieving remission according to the SDAI, CDAI or 
Boolean definition have a greater chance of structural remission than the patients achieving DAS28 remission; 
however, some reports have pointed out the presence of radiographic progression despite the achievement of 
these types of clinical remission [3-5], which reflects the inadequate sensitivity of the conventional approaches 
to detecting synovitis. 
  In this regard, musculoskeletal ultrasonography (MSKUS) is an ideal modality to detect subclinical joint 
inflammation that may lead to further radiographic progression since MSKUS is more sensitive than physical 
examination for detecting joint injury in patients with RA [6-8].  Varying kinds of joint injury including 
articular synovitis, tenosynovitis and bone erosion can be recorded by gray scale (GS) and power Doppler (PD) 
techniques [9, 10].  We have recently reported that the presence of PD synovitis of grade≧2 is a very RA-
specific MSKUS finding among patients with early arthritis [11].  As stated in previous reports, including 
those by us as well as other investigators, PD synovitis has been suggested to reflect the pathologic alterations 
of rheumatoid synovial inflammation in patients with RA better than GS synovitis [8, 12-14].  The qualitative 
importance of subclinical synovitis, as first described by Brown et al., is that the joints with PD signals may 
develop continued structural deterioration irrespective of the achievement of good clinical status in established 
RA patients with a median disease duration of 7 years [8]. 
  Recently, more detailed information regarding PD synovitis in RA patients with good clinical status has been 
accumulated [8, 14-16].  Saleem et al. have revealed that PD synovitis remains in long-standing established 
RA patients achieving clinical remission evaluated by SDAI or Boolean definition [15].  They have also 
shown that those patients in whom PD synovitis remains will develop clinical flare-ups during treatment with 
conventional disease-modifying antirheumatic drugs (DMARDs) [16].  Residual PD synovitis is also 
predictive of clinical flare-ups in early-stage RA patients of mean disease duration of 3.8 months treated by 
conventional DMARDs [14].  These data strongly suggest that the RA patients in clinical remission with 
residual PD synovitis do not achieve “true” remission and are at risk for subsequent structural deterioration 
and flair.  However, the subjects in the above studies exhibited slightly tender or swollen joints upon physical 
examination even if they had achieved clinical remission [8, 14-19].  Therefore, it appears to be desirable to 
select RA patients who have achieved sustained clinical remission without any tender or swollen joints in order 
to examine the characteristics of “real” subclinical PD synovitis in individuals who are almost completely free 
from synovitis by physical examination.  We have serially selected these kinds of patients and tried to 
characterize the residual subclinical PD synovitis in association with biomarkers. 
Materials and Methods 
Patients 
Twenty-nine RA patients who fulfilled the 2010 RA classification criteria [20] were consecutively recruited in 
the present study. All of the patients achieved clinical remission (SDAI≦3.3) for at least 6 months upon 
MSKUS examination. Furthermore, all of the patients exhibited no tender joints among 68 sites and no swollen 
joints among 66 sites upon MSKUS examination.  They were recruited from the Unit of Translational 
Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki 
University from July 2011 through February 2012.  Patients gave their informed consent to be subjected to 
the protocol that was approved by the Institutional Review Board of Nagasaki University.  Serum samples 
were collected and stored at -20 ºC upon MSKUS examination until the assay. 
 
Clinical and laboratory assessment 
Clinical evaluation was performed by Japan College of Rheumatology (JCR)-certified rheumatologists (H.N. 
and A.K.) who were blinded to the MSKUS findings.  Agreement for the presence of tender joints and swollen 
joints by physical examination between the 2 rheumatologists were very high: Kappa coefficient of distribution 
of tender joints was 0.92 and that of swollen joints was also 0.92 in both wrist and finger joints of other active 
5 RA patients.  Disease activity was evaluated by the DAS28- erythrocyte sedimentation rate (ESR), SDAI, 
CDAI and Boolean remission.  In using DAS28-ESR, we followed the criteria set by the European League 
against Rheumatism (EULAR), and in using CDAI and SDAI we followed the method recommended by 
Smolen and colleagues [21].  Boolean remission is defined by all of the following parameters being ≤1 [tender 
joint count (TJC) ≤1, swollen joint count (SJC) ≤1, patient global assessment (PtGA) ≤1 cm, and C-reactive 
protein (CRP) ≤1 mg/dL] [22]. 
  The following laboratory variables were assessed: rheumatoid factor (RF) (Dade Behring, Marburg, 
Germany; cutoff value, 14 IU/ml), anti-cyclic citrullinated peptide antibodies (ACPA) (DIASTAT Anti-CCP, 
Axis-Shield, Dundee, UK; cutoff value, 4.5 U/ml), CRP (Eiken Chemical Co. Ltd., Tokyo, Japan), ESR, matrix 
metalloproteinase-3 (MMP-3) (Daiichi Pure Chemicals, Fukuoka, Japan), vascular endothelial growth factor 
(VEGF) (Quantikine, R&D Systems, Abingdon, UK), angiopoietin-2 (Quantikine, R&D Systems, Abingdon, 
UK), and soluble receptor activator of NF κB ligand (sRANKL) (BIOMEDICA, Wien, Austria).  Clinical 
disease activity as well as serum variables were evaluated on the day of the MSKUS examination.   
 
MSKUS assessment 
Each patient underwent a MSKUS assessment on the same day as the clinical evaluation by a JCR-certified 
rheumatologist (S.K.) who was blinded to the clinical findings (S.K. is also an instructor of MSKUS certified 
by JCR with 7 years experience of MSKUS).  Images from all the examinations were stored, and the US 
scoring reliability was examined in randomly selected patients at the end of the study. A systematic multiplanar 
GS and PD examination of 22 joints was performed with the same scanner (TOSHIBA AplioXG) using a 
multifrequency linear transducer (12 MHz).  The ultrasound score included the following 22 joints: bilateral 
wrists (intracarpal, radiocarpal and ulnocarpal recesses) and finger joints including the 1st -5th 
metacarpophalangeal (MCP) joints, the 1st interphalangeal (IP) joint and the 2nd -5th proximal interphalangeal 
(PIP) joints (dorsal recess).  All joint regions were sonographically examined in a standardized manner 
according to the European League Against Rheumatism (EULAR) [9] and JCR guidelines.  These are the 
same sites where magnetic resonance imaging (MRI) has been performed in patients with early arthritis, as we 
previously described [23, 24].  
  Each joint was scored for GS and PD on a semi-quantitative scale from 0 to 3 [10] (synovial hypertrophy in 
GS: grade 0 = absence, no synovial thickening; grade 1 = mild, minimal synovial thickening filling the angle 
between the periarticular bones without bulging over the line linking the tops of the bones; grade 2 = moderate, 
synovial thickening bulging over the line linking the tops of the periarticular bones but without extension to at 
least one bone diaphysis; grade 3 = marked, synovial thickening bulging over the line linking the tops of the 
periarticular bones and with extension to at least one of the bone diaphyses; PD signals: grade 0 = absence, no 
synovial flow; grade 1 = mild, single-vessel signals; grade 2 = moderate, confluent signals in less than half of 
the synovial area; grade 3 = marked, signals in more than half of the synovial area), and the presence or absence 
of tenosynovitis was noted.  These scores corresponded to the maximum score for GS and PD obtained from 
any of the synovial sites evaluated at each joint.  Tenosynovitis is defined by the presence of abnormal 
hypoechoic or anechoic material with or without fluid inside the tendon sheath with positive PD signals in two 
perpendicular planes [25].  Erosion is defined by a cortical break seen in two perpendicular planes [10]. 
 
Statistical analyses 
Within-group comparisons were made using Mann-Whitney’s U test and the χ2 test (Fisher’s exact probability 
test when appropriate).  Correlations were assessed with Spearman’s correlation coefficient.  The overall 
significance level for statistical analysis was 5% (two-sided).  P values less than 0.05 were considered 
statistically significant.  
 
Results  
Demographic and clinical characteristics in 29 RA patients achieved definitive clinical remission 
The median (range) values of age, disease duration at introducing DMARDs, disease duration at MSKUS 
examination and remission duration at MSKUS examination were 57 (30-80) years-old, 21 (11-300) months, 
and 10 (6-26) months, respectively.  The prevalence rates of ACPA and RF were 86.2 % and 89.7 %, 
respectively.  Twenty-seven patients (93.1%) were treated with conventional DMARDs (23 patients treated 
by methotrexate and 4 patients by salazosulfapyridine) and 12 patients (41.4%) were treated with biological 
agents (5 patients treated by infliximab, 5 patients by etanercept, 1 patient by adalimumab and 1 patient by 
tocilizumab).  DAS28-ESR, CDAI and SDAI were very low; the median (range) of DAS28-ESR was 1.64 
(0.53-2.30), that of CDAI was 0.60 (0-2.00), and that of SDAI was 0.66 (0.01-2.03). All patients achieved 
Boolean remission. In addition, none of the patients exhibited tender or swollen joints.  
 
Residual subclinical synovitis on MSKUS in 29 RA patients achieved definitive clinical remission 
The numbers (percentages) of patients with subclinical synovitis present in at least one joint were GS grade≧
1; 21 (72.4%), GS grade≧2; 10 (34.5%), GS grade 3; 3 (10.3%), PD grade≧1; 17 (58.6%), PD grade≧2; 9 
(31.0%), and PD grade 3; 2 (6.9%). The median (range) GS and PD scores were 2 (0 - 15) and 1 (0 - 12), 
respectively. 
 
Comparison of clinical characteristics between patients with subclinical PD synovitis and patients without PD 
synovitis 
The clinical characteristics were compared between patients with subclinical PD synovitis and patients without 
PD synovitis, and between patients with PD grade≧2 and patients with PD grade 1 or 0 (Table 1).  Age, 
gender, disease duration upon the introduction of DMARDs, disease duration at MSKUS examination, 
remission duration, the prevalence of ACPA and RF, the usage of conventional DMARDs, and disease activity 
were not different among the groups.  In addition, parameters evaluating clinical disease activity at MSKUS 
examination were comparably very low in each group (middle part of Table 1).  However, in the patients with 
PD grade≧2 as compared with patients without, the usage of biological agents was significantly low (p = 
0.032).  The same tendency was also observed between patients with and patients without PD synovitis (p = 
0.12). In addition, regarding to PtGA, PtGA was 0 in 10 patients whereas that was more than 0 in the remaining 
19 patients. The percentage of patients having PD synovitis (70% in patients with PtGA 0 whereas 53 % in 
patients with PtGA more than 0) and total PD score (mean score 2 in patients with PtGA 0 whereas 1 in patients 
with PtGA more than 0) were not different between the above 10 patients and 19 patients. 
 
Comparison of MSKUS findings between patients with subclinical PD synovitis and patients without PD 
synovitis 
The MSKUS findings were also compared between patients with subclinical PD synovitis and patients 
without PD synovitis, and between patients with PD grade≧2 and patients with PD grade 1 or 0 (Table 1).  
As suspected, total PD score was significantly high in the patients with PD synovitis (p < 0.0001) and the 
patients with PD grade≧2 (p = 0.0001).  Additionally, total GS score was significantly higher in the 
patients with PD synovitis (p < 0.0001) and the patients with PD grade≧2 (p = 0.001). Furthermore, the 
percentage of patients with MSKUS bone erosion was significantly higher in the patients with PD synovitis 
(p = 0.032) and the patients with PD grade≧2 (p = 0.0007).  We have confirmed the association of PD 
synovitis and US bone erosion by analyzing their coexistence in a total of 638 joints from 29 patients.  As 
shown in Table 2, there was a marked association between PD synovitis and MSKUS bone erosion (p < 
0.0001).  
 
Comparison of serum biomarkers between patients with subclinical PD synovitis and patients without PD 
synovitis  
Table 3 summarizes the data. Serum concentrations of MMP-3, VEGF, angiopoietin-2 and sRANKL in the 
present 29 patients were comparable with those in normal subjects.  In addition, there were no differences in 
these biomarkers regardless of the presence of PD synovitis or PD grade≧2.  Furthermore, no correlation was 
observed between total PD score and any of the biomarkers (Figure 1).  Since some characteristics distributed 
in the patients with PD synovitis or PD grade≧2 were determined, we have tried to confirm contributions of 
these characteristics by logistic regression analysis [SAS system®, version 9.2 (SAS Institute Inc., Cary, NC, 
USA)].   However, we were not able to obtain definitive results, probably due to the small sample size (data 
not shown).    
Discussion 
Subclinical synovitis is defined as joint inflammation determined not by physical examination but by MSKUS 
or MRI [6-8, 14-17, 26].  The importance of subclinical synovitis, especially as determined by PDUS, has 
been strengthened by several reports showing that its presence is predictive of further radiographic progression 
[14, 27] or clinical flare-ups [14, 27].  To more strictly assess the role of subclinical PD synovitis in patients 
with RA, none of the patients in the present study exhibited tender or swollen joints upon physical examination, 
indicating that our data represent the real nature of subclinical PD synovitis as well as patients who have 
achieved definitive clinical remission with subclinical PD synovitis.  To our knowledge, this is the first 
examination of patients with early-stage RA involved in “true” subclinical PD synovitis. 
  A few reports have explored the characteristics of PD synovitis in Caucasian early-stage RA patients who 
have achieved clinical remission [14, 28].  Although clinical disease activity was lower in the present study 
in comparison with these reports, since some of the patients in previous reports exhibited tender or swollen 
joints, the percentage of patients with PD synovitis was higher in the present study than in the previous reports 
[14, 28].  The positivity rates of ACPA (29% in ref. 14) and RF (39% in ref. 14 and 41% in ref. 28) in the 
present cases were much higher than in the previous cases, which may influence the results. Alternatively, 
Japanese RA patients might be more susceptible to joint inflammation as compared with Caucasian RA patients. 
However, these points need to be clarified in further studies. 
  In addition, we have revealed the characteristics of early-stage RA patients with subclinical PD synovitis. 
With regard to therapies, the absence of PD synovitis was likely to be associated with biological agents. There 
is increasing evidence that biological agents are superior to conventional DMARDs in terms of radiographic 
progression [1, 29, 30].  Since the existence of PD signals is a risk factor for further radiographic progression 
in patients with RA [8, 27], the suppression of PD signals by biological agents may explain the preferential 
protective effect toward joint damage as compared with conventional DMARDs.  Furthermore, the percentage 
of patients with US bone erosion was higher in those with subclinical PD synovitis than in those without PD 
synovitis. Additionally, the frequency of the joints with US bone erosion was much higher in the joints with 
PD signals as compared with the joints without PD signals.  These data indicate that the coexistence of PD 
signals with US bone erosion is a characteristic feature of US images in patients with early-stage RA even after 
they have achieved definitive clinical remission.  It would be reasonable for patients with PD synovitis to 
show a high GS score in the present study, since the severity of the PD score usually correlates with that of the 
GS score in patients with RA.  Considering that the presence of PD signals predicts further radiographic 
progression [8, 27], subclinical PD synovitis is thought to be pathologically still active, and is thus supposed 
to coexist with US bone erosion, possibly leading to further joint damage. However, longitudinal observation 
is necessary to confirm the above speculation.  
  PD signals with GS thickening of synovial tissues in RA patients reflect synovial cell hyperplasia with 
neovascularization [31, 32].  Therefore, high serum concentrations of MMP-3, RANKL, and angiogenesis 
factors along with acute phase reactants are commonly observed in patients with RA [33-35].  In this regard, 
we and other investigators have revealed increments of serum VEGF, angiopoietin-1 and angiopoietin-2 in RA 
patients that are correlated with clinical disease activity [36, 37].  Scire et al. previously reported a correlation 
of PD measures with CRP in patients with early-stage RA, although this correlation was very low as compared 
with active disease [14].  In comparison to the results by Scire et al., CRP, ESR, MMP-3, VEGF, angiopoietin-
2 and RANKL remained in the normal ranges regardless of the presence or absence of subclinical PD synovitis 
in the present study. Furthermore, there were no correlations between PD sores and CRP, ESR, MMP-3, VEGF, 
angiopoietin-2 or RANKL in the present study.  Since all of the present cases achieved more stringent 
remission as compared with the cases in the report by Scire et al. [14], no correlation could be determined.  At 
this point, the presence of US bone erosion or a higher GS score is believed to be a very relevant finding for 
predicting the presence of subclinical PD synovitis in patients who have achieved definitive clinical remission.  
Alternatively, the use of conventional biomarkers may not be enough to identify the remnant disease activity, 
and more global analysis may be warranted to seek the biomarkers that differentiate the presence or absence 
of imaging remission.    
  There are some limitations in the present study.  We were not able to validate the multivariate analysis, 
probably due to the small sample size. Also, this is not a randomized control trial but an observational study; 
therefore, the choice of DMARDs depended on each physician’s preference. These differences might affect the 
distribution of subclinical PD synovitis. Larger-scale randomized controlled trials are needed to confirm our 
present findings.  However, as stated by the Targeted Ultrasound Initiative Group [38], the suppression of 
residual PD synovitis is suggested to be a target to achieve in imaging remission.  Thus, our present data may 
emphasize the importance of subclinical PD synovitis and suggest that it may be an ideal surrogate marker in 
the attempt to achieve complete remission in patients with RA, especially in the earlier stages of the disease 





・ PD subclinical synovitis still remains in RA patients achieveing clinical remission free from physical 
synovitis. 
・ Conventional biomarkers may not be enough to identify the remnant disease activity. 
・ PD subclinical synovitis may be an ideal surrogate marker to accomplish complete remission of RA. 
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Figure Legends 
Figure 1. Correlation between total PD score and serum biomarkers. 
No correlation between total PD score and any of the biomarkers was observed.  Correlations were assessed 
with Spearman’s correlation coefficient.   
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase-3; VEGF, 
vascular endothelial growth factor; Ang-2, angiopoietin-2, sRANKL, soluble receptor activator of NF κB 























































































Table 1. Comparison of clinical characteristics and MSKUS findings between patients with PD-positive synovitis and patients without PD- 
positive synovitis. 




P PD grade 0/1 
(n=20) 
PD grade 2/3 
(n=9) 
p 
Age; years a  50.5 (30-72) 57.0 (35-80) 0.36 59.5 (30-80) 56 (35-74) 0.49 
Gender; Female / Male  9 / 3 13 / 4 0.70 15 / 5 7 / 2 0.63 
Disease duration at introduction of 
DMARDs; months a 
3 (1-36) 3 (1-36) 0.95 3 (1-36) 2 (2-6) 0.85 
Disease duration  
  at MSKUS examination; months a  
20 (12-67) 21 (11-300) 0.64 20 (11-67) 21 (11-300) 0.46 
Duration of remission; months a  11 (6-24) 10 (6-26) 0.95 9.5 (6-26) 12 (6-21) 0.48 
Positivity of ACPA; n (%) 10 (83.3) 15 (88.2) 0.56 16 (80.0) 9 (100) 0.20 
Positivity of RF; n (%)  10 (83.3) 16 (94.1) 0.75 18 (90.0) 8 (88.9) 0.78 
Conventional DMARDs therapy; n (%)  10 (83.3) 17 (100) 0.16 18 (90.0) 9 (100) 0.47 
Biological therapy; n (%)  7 (58.3) 5 (29.4) 0.12 11 (55.0) 1 (11.1) 0.03 
Concomitant steroid; n (%) 0 (0) 0 (0) - 0 (0) 0 (0) - 
Tender joint counts; n/68  0 0 - 0 0 - 
Swollen joint counts; n/66  0 0 - 0 0 - 
PtGA; mm a  3 (0-10) 3 (0-10) 0.38 3 (0-10) 0 (0-10) 0.13 
EGA; mm a  3 (0-8) 3 (0-10) 0.54 3 (0-10) 1 (0-10) 0.27 









ESR; mm/hr a  9 (2-25) 11 (4-20) 0.13 10.5 (2-25) 8 (4-14) 0.10 









CDAI a  0.65 (0-1.80) 0.60 (0-2.00) 0.48 0.60 (0-1.80) 0.10 (0-2.00) 0.25 









Boolean remission; n(%)  12 (100) 17 (100) - 20 (100) 9 (100) - 
MSKUS findings       
Total GS score a  0 (0-2) 4 (1-15) <0.0001 1 (0-11) 4 (2-15) 0.001 
Total PD score a  0 2 (1-12) <0.0001 0 (0-4) 3 (2-12) 0.0001 
  Tenosynovitis; n (%)  2 (16.7) 4 (23.5) 0.51 3 (15.0) 3 (33.3) 0.53 
  Bone erosion; n (%)  1 (8.3) 8 (47.1) 0.03 2 (10.0) 7 (77.8) <0.001 
aMedian (range)    
Within-group comparisons were assessed with Mann-Whitney’s U test and χ2 test 
MSKUS, musculoskeletal ultrasonography; RF, rheumatoid factor, ACPA, anti-cyclic citrullinated peptide antibody; PGA, patient global 
assessment; EGA, evaluator global assessment; DAS28, disease activity score 28; CDAI, clinical disease activity index; SDAI, simplified 
disease activity index; GS, gray scale; PD, power Doppler 
 
Table 2. Comparison between PD positive synovitis and MSKUS bone erosion 
 PD negative PD positive  
Bone erosion negative 600 21  
P<0.0001 Bone erosion positive 7 10 
Within-group comparisons were assessed with χ2 test. 
PD, power Doppler 
 
Table 3. Comparison of serum biomarkers between patients with PD-positive synovitis and patients without PD-positive synovitis. 




p PD grade 0/1 
(n=20) 
PD grade 2/3 
(n=9) 
P 




































Serum levels (median (range)) of healthy controls (n=10); VEGF 291(32-602) pg/ml, angiopoietin-2 1827(1230-2587) pg/ml, 
ampli-sRANKL 0.009 (0-0.308) pmol/L  
Within-group comparisons were assessed with Mann-Whitney’s U test. 
PD, power Doppler; MSKUS, musculoskeletal ultrasonography; MMP-3, matrix metalloproteinase-3; VEGF, vascular endothelial growth 
factor; sRANKL, soluble receptor activator of NF κB ligand 
